For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

A new partnership will create a theranostics health care platform in the region with radiopharmaceutical production and therapy, molecular imaging, and clinical trials all at the same location. One ...

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

More than 1,300 people waited longer than they should have for cancer treatment in 2025.

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

Registration is now open for the “New Developments in PCNSL Treatment” online educational event on March 27th, 2026, ...